Shire Share Discussion Threads

[topdoc] 28/10/2011 10:51

should get a good boost after results hopefully

[aimshares] 03/10/2011 20:56

A big pharma will licence there drugs or will do a takeover of Verona pharma listed on Aim.

[nellie1973] 16/6/2011 15:37

Conviction buy target 2300p

[stuart14] 20/4/2011 11:22

Nice chart either way!!

[the_doctor] 19/4/2011 17:06

I'm not sure it's as yet priced over what Sanofi paid for genzyme
I see GSK or Teva as most likely suitors
It could well happen, although I do think Shire's pipeline is lacking.

[stuart14] 19/4/2011 17:03

Nice chart. Any chance of an offer here?

[mellorscarthwaite] 21/3/2011 11:47

NEW YORK (TheStreet) -- Shire (Nasdaq:SHPGY) hit a new 52-week high Friday as it traded at $88.14 compared with its previous 52-Week high of $87.64. Shire is changing hands at $87.80 with 118,797 shares traded as of 9:37 a.m. ET. Average volume has been 431,200 shares over the past 30 days.
Shire has a market cap of $15.7 billion and is part of the health care sector and drugs industry. Shares are up 19.2% year to date as of the close of trading on Thursday.
Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company operates through two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 26.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 15.6.
TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

[harrybigdick] 20/3/2011 01:06

I am now looking at shorting this naughty girl, from the rear.
I will let go of her circa £8-£10.

Hope this helps
Sanks

[mellorscarthwaite] 25/2/2011 15:04

Back on trend WHOOOOOOOSH

SHIRE BULLISH MOVING AVERAGE CROSSOVER ALERT (SHPGY)Print Share Feb 25, 2011 (SmarTrend(R) Market Surveillance via COMTEX) -- Today, shares of Shire (NASDAQ:SHPGY) have crossed bullishly above their 10-day moving average of $82.59 on volume of 192 thousand shares.

This may provide swing traders with an opportunity for a long position as such a crossover often suggests higher prices in the near term. Watch for a close above this moving average level for confirmation.

SmarTrend issued an Uptrend Alert for Shire on September 08, 2010 at $67.34. In approximately 6 months, Shire has returned 22.3% as of today's recent price of $82.36.

In the past 52 weeks, shares of Shire have traded between a low of $56.60 and a high of $84.62 and are now at $82.36, which is 46% above that low price.

In the last five trading sessions, the 50-day MA has climbed 0.86% while the 200-day MA has risen 0.38%.

We will continue to monitor SHPGY's share price relative to this moving average

[the_doctor] 23/2/2011 11:43

My expectation is for this drop to extend to 1600 or 1580

[mellorscarthwaite] 16/2/2011 15:43

BREAKOUT

Shares of Shire ADR Reptg 3 Ord Shs (SHPGY) hit a new 52-week high on Tuesday. The stock traded as high as $82.96 during mid-day trading and last traded at $82.46. The stock previously closed at $82.23.

On a related note, analysts at RBC Capital (NYSE: RY) raised their price target on shares of Shire ADR Reptg 3 Ord Shs from $78.00 to $84.00 in a research note to investors on Monday, February 7th. They now have a "sector perform" rating on the stock. Separately, analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of Shire ADR Reptg 3 Ord Shs from $80.00 to $92.00 in a research note to investors on Tuesday, January 18th. They now have a "buy" rating on the stock.

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases, as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets. The Company markets its products under various trademarks, including VYVANSE, ELAPRASE, LIALDA / MEZAVANT, PENTASA, REPLAGAL, FOSRENOL, FIRAZYR, INTUNIV and VPRIV.

Shares of Shire ADR Reptg 3 Ord Shs (SHPGY) traded up 0.69% during mid-day trading on Tuesday, hitting $82.80. Shire ADR Reptg 3 Ord Shs has a 52 week low of $56.60 and a 52 week high of $82.30. The stock's 50-day moving average is $77.29 and its 200-day moving average is $71.68. On average, analysts predict that Shire ADR Reptg 3 Ord Shs will post $1.16 EPS next quarter. The company has a market cap of $15.105 billion and a price-to-earnings ratio of 25.57.

[the_doctor] 16/2/2011 10:02

Right, IMO it's too high
I'm now short.

[the_doctor] 08/12/2010 20:29

bump....

get up, I'd like to go short...

[brain smiley] 25/2/2010 12:29

Shares in Shire (SHP.L) gain 1.8 percent, heading a firmer drugs sector, after BofA Merrill Lynch boosts its target price for the firm to 1,630 pence, up from 1,400 pence after raising its EPS forecasts by 15-20 percent following recent 2009 results.
Merrill says its EPS upgrades are based on higher sales of Shire's three key products -- Adderall XR, VPRIV and Replagal -- as well as on slower research & development and selling, general and administrative expenses growth.

"With Shire offering one of the fastest growth rates in the sector, further EPS upside still possible and pipeline catalysts beginning to appear on the horizon we maintain our Buy rating," Merrill says.

[the_doctor] 25/2/2010 10:02

Boing! Yes. SHP doing well.
The threat of a bid puts me off going short, so will see how high it can get first.

[togo2] 25/2/2010 10:00

Out at 1397 ,It will prabably go over 1400 now!

[brain smiley] 24/2/2010 16:11

Pharma groups were in focus after the Obama administration renewed its push for healthcare reform in the United States, with AstraZeneca easing by 20p to 2810p. Elsewhere, GlaxoSmithKline, down 2.6 per cent or 31.5p at 1203.5p, suffered after US lawmakers published a critical report on its Avandia diabetes drug. Sector peer Shire was under pressure in early trading, touching a session low of 1338p, down 2.3 per cent, after Panmure Gordon turned negative on valuation grounds. "Shire is currently trading on a price to earnings multiple of 18.2 times for 2010 and 16.6 times for 2011, representing a premium of 22.5 per cent and 21.9 per cent to the mid-cap European pharmaceutical sector. Importantly [it is] also at a 60 per cent premium to the large-cap pan-European pharmaceutical sector," the broker said. The stock recovered to 1380p, up 10p, by the close, with market watchers citing the impact of positive commentary from Oppenheimer.

[philo124] 23/2/2010 15:19

Yes bad timing on sale i agree; bought at 874p so some consolation.

[the_doctor] 19/2/2010 16:30

Anyone get on the short? 13:08 pretty much marked the top.

This'll get some press over the weekend, so I've closed.
Will look for another short next week.

[the_doctor] 19/2/2010 13:16

Someone probably got rather burnt there!

[the_doctor] 19/2/2010 13:08

This is now too high IMO

[togo2] 19/2/2010 12:15

Bad mistake phil.

[philo124] 18/2/2010 08:54

Sold @1294p.